Who are BAT8001 for injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SHR-A1811 for Injection, Ponatinib + Blinatumomab, AK117 in combination with AK112, Amivantamab Intravenous, VB4-845 Injection, KN026.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bat8001-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

BAT8001 for injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAT8001 for injection (BAT8001 for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific monoclonal antibody. Area: Oncology.

phase 3 Bispecific monoclonal antibody Oncology Biologic Live · refreshed every 30 min

Target snapshot

BAT8001 for injection (BAT8001 for injection) — Bio-Thera Solutions. BAT8001 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BAT8001 for injection TARGET	BAT8001 for injection	Bio-Thera Solutions	phase 3	Bispecific monoclonal antibody
SHR-A1811 for Injection	SHR-A1811 for Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor
Ponatinib + Blinatumomab	Ponatinib + Blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor, Bispecific monoclonal antibody	BCR-ABL1, CD19, CD3
AK117 in combination with AK112	AK117 in combination with AK112	Akeso	phase 3	Bispecific monoclonal antibody	PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112)
Amivantamab Intravenous	Amivantamab Intravenous	Janssen Research & Development, LLC	phase 3	Bispecific monoclonal antibody	EGFR and MET
VB4-845 Injection	VB4-845 Injection	Qilu Pharmaceutical Co., Ltd.	phase 3	Bispecific monoclonal antibody	VEGF and HER2
KN026	KN026	Shanghai JMT-Bio Inc.	phase 3	Bispecific monoclonal antibody	HER2 and HER3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific monoclonal antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shanghai JMT-Bio Inc. · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
Xianmin Song, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAT8001 for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/bat8001-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing